Cytosorbents Corp
NASDAQ:CTSO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.6215
1.31
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Cytosorbents Corp
Cash from Operating Activities
Cytosorbents Corp
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Cytosorbents Corp
NASDAQ:CTSO
|
Cash from Operating Activities
-$10m
|
CAGR 3-Years
29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-1%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash from Operating Activities
$3.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
7%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
57%
|
CAGR 5-Years
25%
|
CAGR 10-Years
21%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash from Operating Activities
$4.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
12%
|
CAGR 10-Years
18%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Operating Activities
$9.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Operating Activities
$3B
|
CAGR 3-Years
22%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
|
Cytosorbents Corp
Glance View
CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Monmouth Junction, New Jersey and currently employs 221 full-time employees. The company went IPO on 2005-06-17. The firm is engaged in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via its polymer adsorption technology. The firm's lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy and pancreatitis. Its other products include animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. The firm's product candidates under development includes CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent and porous polymer beads.
See Also
What is Cytosorbents Corp's Cash from Operating Activities?
Cash from Operating Activities
-10m
USD
Based on the financial report for Sep 30, 2025, Cytosorbents Corp's Cash from Operating Activities amounts to -10m USD.
What is Cytosorbents Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-1%
Over the last year, the Cash from Operating Activities growth was 46%. The average annual Cash from Operating Activities growth rates for Cytosorbents Corp have been 29% over the past three years , -3% over the past five years , and -1% over the past ten years .